Epitope specificity determines pathogenicity and detectability in anca-associated vasculitis

Journal of Clinical Investigation

Volumn 123, Issue 4, 2013, Pages 1773-1783

  Roth, Aleeza J ^a   Ooi, Joshua D ^b   Hess, Jacob J ^a   Van Timmeren, Mirjan M ^c   Berg, Elisabeth A ^a   Poulton, Caroline E ^a   McGregor, JulieAnne ^a   Burkart, Madelyn ^a   Hogan, Susan L ^a   Hu, Yichun ^a   Winnik, Witold ^d   Nachman, Patrick H ^a   Stegeman, Coen A ^c   Niles, John ^e   Heeringa, Peter ^c   Kitching, A Richard ^b   Holdsworth, Stephen ^b   Jennette, J Charles ^a   Preston, Gloria A ^a   Falk, Ronald J ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; EPITOPE; IMMUNOGLOBULIN G; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ARTICLE; CELL ACTIVATION; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; NEPHRITIS; NEUTROPHIL; PATHOGENICITY; PRIORITY JOURNAL; SEROLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; ANIMALS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODY SPECIFICITY; AUTOANTIBODIES; CASE-CONTROL STUDIES; CERULOPLASMIN; CHILD; EPITOPES; FEMALE; HUMANS; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PEROXIDASE; YOUNG ADULT;

EID: 84875827100     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI65292     Document Type: Article

References (32)

1. Tervaert JW, Stegeman CA, Kallenberg CG. Serial ANCA testing is useful in monitoring disease activity of patients with ANCA-associated vasculitides. Sarcoidosis Vasc Diffuse Lung Dis. 1996;13(3):241-245.
2. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A. 1990;87(11):4115-4119.
3. Xiao H, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002; 110(7):955-963.
4. Chen M, Kallenberg CG, Zhao MH. ANCA-negative pauci-immune crescentic glomerulonephritis. Nat Rev Nephrol. 2009;5(6):313-318.
5. Hogan SL, Nachman PH, Wilkman AS, Jennette JC, Falk RJ. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996;7(1):23-32.
6. Pagnoux C, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: Comparison of two independent cohorts. Arthritis Rheum. 2008; 58(9):2908-2918.
7. Cui Z, Zhao MH, Segelmark M, Hellmark T. Natural autoantibodies to myeloperoxidase, proteinase 3, and the glomerular basement membrane are present in normal individuals. Kidney Int. 2010; 78(6):590-597.
8. Olson SW, et al. Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease. J Am Soc Nephrol. 2011;22(10):1946-1952.
9. Parker CE, Tomer KB. MALDI/MS-based epitope mapping of antigens bound to immobilized antibodies. Mol Biotechnol. 2002;20(1):49-62.
10. Mirza SP, Greene AS, Olivier M. 18O labeling over a coffee break: A rapid strategy for quantitative proteomics. J Proteome Res. 2008;7(7):3042-3048.
11. Kingston IB, Kingston BL, Putnam FW. Chemical evidence that proteolytic cleavage causes the heterogeneity present in human ceruloplasmin preparations. Proc Natl Acad Sci U S A. 1977;74(12):5377-5381.
12. Ooi JD, et al. The immunodominant myeloperoxidase T-cell epitope induces local cell-mediated injury in antimyeloperoxidase glomerulonephritis. Proc Natl Acad Sci U S A. 2012;109(39):E2615-E2624.
13. Chen M, Yu F, Wang SX, Zou WZ, Zhao MH, Wang HY. Antineutrophil cytoplasmic autoantibodynegative Pauci-immune crescentic glomerulonephritis. J Am Soc Nephrol. 2007;18(2):599-605.
14. Ara J, Pascual J, Mirapeix E, Rodriguez R, Abellana R, Darnell A. Ceruloplasmin in small vessel vasculitis. Nephrol Dial Transplant. 1999;14(2):515-517.
15. Baskin E, et al. Ceruloplasmin levels in antineutrophil cytoplasmic antibody-positive patients. Pediatr Nephrol. 2002;17(11):917-919.
16. Griffin SV, Chapman PT, Lianos EA, Lockwood CM. The inhibition of myeloperoxidase by ceruloplasmin can be reversed by anti-myeloperoxidase antibodies. Kidney Int. 1999;55(3):917-925.
17. Pedrollo E, Bleil L, Bautz FA, Kalden JR, Bautz EK. Antineutrophil cytoplasmic autoantibodies (ANCA) recognizing a recombinant myeloperoxidase subunit. Adv Exp Med Biol. 1993;336:87-92.
18. Fujii A, et al. Epitope analysis of myeloperoxidase (MPO) specific anti-neutrophil cytoplasmic autoantibodies (ANCA) in MPO-ANCA-associated glomerulonephritis. Clin Nephrol. 2000;53(4):242-252.
19. Tomizawa K, et al. A panel set for epitope analysis of myeloperoxidase (MPO)-specific antineutrophil cytoplasmic antibody MPO-ANCA using recombinant hexamer histidine-tagged MPO deletion mutants. J Clin Immunol. 1998;18(2):142-152.
20. Suzuki K, et al. Analysis of risk epitopes of antineutrophil antibody MPO-ANCA in vasculitis in Japanese population. Microbiol Immunol. 2007; 51(12):1215-1220.
21. Erdbrugger U, et al. Mapping of myeloperoxidase epitopes recognized by MPO-ANCA using human-mouse MPO chimers. Kidney Int. 2006;69(10):1799-1805.
22. Bruner BF, Vista ES, Wynn DM, James JA. Epitope specificity of myeloperoxidase antibodies: Identification of candidate human immunodominant epitopes. Clin Exp Immunol. 2011;164(3):330-336.
23. Xu PC, Cui Z, Chen M, Hellmark T, Zhao MH. Comparison of characteristics of natural autoantibodies against myeloperoxidase and anti-myeloperoxidase autoantibodies from patients with microscopic polyangiitis. Rheumatology (Oxford). 2011; 50(7):1236-1243.
24. Jennette JC, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37(2):187-192.
25. Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996;7(1):33-39.
26. Csernok E, et al. Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: First results from a multicentre study. Rheumatology (Oxford). 2004;43(2):174-180.
27. Tervaert JW, et al. Occurrence of autoantibodies to human leucocyte elastase in Wegener's granulomatosis and other inflammatory disorders. Ann Rheum Dis. 1993;52(2):115-120.
28. Savige J, et al. Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. Am J Clin Pathol. 2003;120(3):312-318.
29. Rich C, et al. Myelin oligodendrocyte glycoprotein-35-55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice. Eur J Immunol. 2004; 34(5):1251-1261.
30. Lock RJ. ACP Broadsheet No 143: January 1994.
31. Detection of autoantibodies to neutrophil cytoplasmic antigens. J Clin Pathol. 1994;47(1):4-8.
32. Ooi JD, Phoon RK, Holdsworth SR, Kitching AR. IL-23, not IL-12, directs autoimmunity to the Goodpasture antigen. J Am Soc Nephrol. 2009; 20(5):980-989.